Comparing effectiveness and safety of combination therapy for esophageal and gastro esophageal junction cancer: a comprehensive meta-analysis

This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριος συγγραφέας: Abir, Shifaty Nur
Άλλοι συγγραφείς: Jamiruddin, Mohd. Raeed
Μορφή: Thesis
Γλώσσα:English
Έκδοση: Brac University 2024
Θέματα:
Διαθέσιμο Online:http://hdl.handle.net/10361/23251
id 10361-23251
record_format dspace
spelling 10361-232512024-06-09T21:01:14Z Comparing effectiveness and safety of combination therapy for esophageal and gastro esophageal junction cancer: a comprehensive meta-analysis Abir, Shifaty Nur Jamiruddin, Mohd. Raeed School of Pharmacy, Brac University Gastroesophageal cancer Immunotherapy Chemotherapy Esophageal cancer GEJC Cancer--Treatment Cancer--Chemotherapy Esophagogastric junction--Cancer This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023. Cataloged from the PDF version of thesis. Includes bibliographical references (pages 27-33). Introduction: In cases of resectable esophageal cancer, neoadjuvant immune checkpoint inhibitors and chemotherapy have been examined. Nonetheless, conflicting findings have been found in subsequent research. Thus, meta-analysis was the main purpose to methodically evaluate the safety and effectiveness profiles of immune treatment and chemotherapy combinations in individuals with esophageal cancer (EPC) or gastro-esophageal junction cancer (GEJC). Method: Through a combination of MeSH (Medical Subject Headings) and keyword searches, “esophageal cancer”, “chemotherapy combination”, and “immunotherapy combination” in several databases, including the Google scholar, Researchgate, PubMed, and ClinicalTrials.gov websites, several articles were thoroughly reviewed and clinical randomized controlled trials (RCTs) were gathered by 2022. The Cochrane Methods were used to standardize the selection process, collect data from the studies, and evaluate the superiority of evidence and risk of bias. The primary measures were the estimated 95% CIs for the hazard ratio (HR) and odds ratio (OR) for overall survival (OS), progression-free survival (PFS), overall adverse events (OAE), and severe adverse events (SAE). R studio was used to evaluate the results, and online RobVis was also used for bias analysis. Result: This meta-analysis looked at 15 RCTs with a total of 4,021 individuals to determine the effectiveness and safety of immunotherapy and chemotherapy for esophageal cancer. The outcomes demonstrated that the chemotherapy and immunotherapy treatment was linked with an overall risk for OS [HR = 0.85, 95% CI: 0.72–1.00; p < 0.71], PFS [HR = 0.94, 95% CI: 0.80–1.11]; p < 0.001], SAE (OR) = [0.99, 95% CI: 0.58–1.70; p = 0.08] and OAE (OR) = [0.72, 95% CI: 0.36–1.44; p = <0.01]. To determine the final result, Random Effects Model was utilised. The adverse event profile consisted of a combination of severe forms, such as anemia, thrombocytopenia, neutropenia, and diarrhea, among other types. Thankfully, toxicities were within tolerable limits. Conclusion: This research indicates that individuals with advanced, untreatable, or metastatic EPC/GEJ who have not got any conventional prior treatment will clearly benefit from immunotherapy and chemotherapy combination. Nonetheless, there is a significant chance that immunotherapy and chemotherapy can cause adverse responses, therefore more research on the management of untreated, incurable, advanced, or metastatic EPC/GEJ is necessary. Shifaty Nur Abir B. Pharmacy 2024-06-09T06:14:41Z 2024-06-09T06:14:41Z ©2023 2023-12 Thesis ID: 18346008 http://hdl.handle.net/10361/23251 en Brac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. 46 pages application/pdf Brac University
institution Brac University
collection Institutional Repository
language English
topic Gastroesophageal cancer
Immunotherapy
Chemotherapy
Esophageal cancer
GEJC
Cancer--Treatment
Cancer--Chemotherapy
Esophagogastric junction--Cancer
spellingShingle Gastroesophageal cancer
Immunotherapy
Chemotherapy
Esophageal cancer
GEJC
Cancer--Treatment
Cancer--Chemotherapy
Esophagogastric junction--Cancer
Abir, Shifaty Nur
Comparing effectiveness and safety of combination therapy for esophageal and gastro esophageal junction cancer: a comprehensive meta-analysis
description This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.
author2 Jamiruddin, Mohd. Raeed
author_facet Jamiruddin, Mohd. Raeed
Abir, Shifaty Nur
format Thesis
author Abir, Shifaty Nur
author_sort Abir, Shifaty Nur
title Comparing effectiveness and safety of combination therapy for esophageal and gastro esophageal junction cancer: a comprehensive meta-analysis
title_short Comparing effectiveness and safety of combination therapy for esophageal and gastro esophageal junction cancer: a comprehensive meta-analysis
title_full Comparing effectiveness and safety of combination therapy for esophageal and gastro esophageal junction cancer: a comprehensive meta-analysis
title_fullStr Comparing effectiveness and safety of combination therapy for esophageal and gastro esophageal junction cancer: a comprehensive meta-analysis
title_full_unstemmed Comparing effectiveness and safety of combination therapy for esophageal and gastro esophageal junction cancer: a comprehensive meta-analysis
title_sort comparing effectiveness and safety of combination therapy for esophageal and gastro esophageal junction cancer: a comprehensive meta-analysis
publisher Brac University
publishDate 2024
url http://hdl.handle.net/10361/23251
work_keys_str_mv AT abirshifatynur comparingeffectivenessandsafetyofcombinationtherapyforesophagealandgastroesophagealjunctioncanceracomprehensivemetaanalysis
_version_ 1814307443891503104